Earnings Call Transcripts

Access detailed transcripts and key takeaways from company earnings calls

All Earnings Calls

WAVE May 12, 2026

Eco Wave Power Q1 2026 Earnings Call - Wave Energy Positioned for AI Infrastructure Boom

Eco Wave Power reported a tighter operating loss of $682,000 in Q1 2026, down from $765,000 a year prior, driven by disciplined cost cuts across R&D, sales, and administration. The company holds $5.3 ...

  • Operating expenses fell 11% year-over-year to $682,000, with R&D dropping to $140,000 from $181,000 and G&A down to $499,000 from $539,000.
  • Operating loss improved to $682,000 from $765,000 in Q1 2025, though net loss widened to $695,000 due to foreign exchange fluctuations.
  • The company maintains $5.3 million in total liquidity as of March 31, 2026, ensuring runway for ongoing operations and project development.
  • +7 more takeaways
MAPS May 12, 2026

WM Technology Q1 2026 Earnings Call - Strategic Delisting and Cannabis Rescheduling Unlocks Next Phase

WM Technology reported Q1 2026 revenue of $43.6 million, down 2% year-over-year but in line with expectations. The company navigated a difficult operating environment marked by price compression, elev...

  • Revenue for Q1 2026 was $43.6 million, down 2% year-over-year but up 1% sequentially, aligning with management expectations.
  • Average monthly paying clients declined 4% year-over-year to approximately 4,983, primarily due to churn in mature markets like California, Michigan, and Colorado.
  • Client churn was driven by financial stress, price compression, and non-payment issues among operators in saturated markets.
  • +7 more takeaways
NOVT May 12, 2026

Novanta Inc Q1 2026 Earnings Call - Bookings Surge 37% as AI and Medical Tech Drive Broad-Based Momentum

Novanta delivered a sharp turn in momentum in Q1 2026, with organic revenue growth accelerating to 3% and bookings jumping 37% year-over-year. The company is riding a broad-based wave of demand across...

  • Bookings surged 37% year-over-year with a book-to-bill ratio of 1.10, signaling robust demand across all business units and setting the stage for accelerated revenue growth.
  • Organic revenue growth accelerated to 3% in Q1 2026, with management raising full-year guidance to expect organic growth of up to 6%, reflecting a clear inflection in momentum.
  • New product revenue jumped 50% year-over-year, and design wins were up nearly 30%, validating the company’s innovation-driven strategy and sticky OEM partnerships.
  • +7 more takeaways
AMBQ May 12, 2026

Ambiq Micro Q1 2026 Earnings Call - Edge AI Demand Outpaces Supply, Diversification Gains Traction

Ambiq Micro delivered a sharp start to 2026, with Q1 net sales of $25.1 million beating guidance and rising 59% year-over-year. The growth was driven by broad-based demand for edge AI across wearables...

  • Q1 2026 net sales reached $25.1 million, up 59.3% year-over-year and beating guidance, driven by strong demand for edge AI across wearables and new markets.
  • Over 80% of Ambiq’s units now run AI algorithms, with demand accelerating across form factors including watches, rings, and smart eyewear.
  • The company successfully diversified its customer base, reducing the revenue share of its top three customers from 86% in Q1 2025 to 71% in Q1 2026.
  • +7 more takeaways
TIGO May 12, 2026

Millicom Q1 2026 Earnings Call - Coltel Integration and Chile Turnaround Drive Record Cash Flow

Millicom delivered a robust Q1 2026, driven by the consolidation of Coltel in Colombia and the successful application of its turnaround playbook in Ecuador and Uruguay. Reported service revenue surged...

  • Reported service revenue jumped 45% YoY to $1.9 billion, driven by the consolidation of Coltel; organic service revenue growth remained a healthy 4.9%.
  • Adjusted EBITDA reached $857 million with a 43.2% margin; excluding Coltel, the margin expanded to 47.9%, highlighting underlying operational strength.
  • Equity free cash flow hit a record Q1 of $225 million, up 66% year-over-year, supported by disciplined cost management and FX tailwinds.
  • +7 more takeaways
SAMG May 12, 2026

Silvercrest Asset Management Q1 2026 Earnings Call - Heavy Investment Costs Weigh on Margins Amid Global Expansion

Silvercrest Asset Management entered its 25th year with a clear strategic pivot toward global expansion, but the Q1 2026 financials reflect the heavy price tag of that ambition. Discretionary AUM fell...

  • Discretionary AUM declined 3.7% sequentially to $23.1 billion, driven by net institutional outflows, though year-over-year discretionary AUM grew nearly 2%.
  • Total AUM increased 1.1% year-over-year to $35.7 billion, with management noting a future accounting change will lower non-discretionary AUM reporting without impacting revenue.
  • Revenue remained flat at $31.4 million year-over-year, while expenses rose 13.5% to $22.4 million, primarily due to increased compensation and administrative costs.
  • +9 more takeaways
NPWR May 12, 2026

NET Power Q1 2026 Earnings Call - Commercial Offtake Process Gating Capital Commitment for Permian Phase I

NET Power is pivoting hard from engineering to commercialization, making the offtake process for Project Permian Phase I the single most critical milestone. The company is holding back on major capita...

  • NET Power is prioritizing commercial offtake agreements as the gating condition for project financing and capital deployment for Project Permian Phase I.
  • The company has $319 million in cash and no debt, providing ample runway to reach final investment decision while maintaining a low quarterly burn rate of $8 million to $9 million.
  • Project Permian Phase I targets 80 MW net output with over 90% CO2 capture, sited in West Texas with plans to scale to 800 MW on the same acreage.
  • +7 more takeaways
SLSN May 12, 2026

Solesence Q1 2026 Earnings Call - Gross Margins Expand as Operational Overhaul Drives Near-Term Revenue Miss

Solesence reported a revenue decline to $13 million in Q1 2026, a clear miss driven by On-Time In-Full (OTIF) execution failures during its transition to a new supply chain model. The company’s pivot ...

  • Revenue declined 11% year-over-year to $13 million, down from $14.6 million in Q1 2025, primarily due to On-Time In-Full (OTIF) shipment delays rather than a drop in customer demand.
  • Gross margin expanded by 300 basis points to 26%, driven by improved labor efficiency and the elimination of product quality-related waste that plagued the prior year.
  • Net income swung to a $0.8 million loss from a $0.08 million profit in the prior year, reflecting near-term investments in operational infrastructure and organizational realignment.
  • +9 more takeaways
PTRN May 12, 2026

Pattern Q1 2026 Earnings Call - Record 127% Net Revenue Retention Drives Raised Guidance

Pattern delivered a record first quarter for 2026, with revenue surging 43% year-over-year to $774 million and adjusted EBITDA climbing 59% to $54 million. The company raised its full-year revenue out...

  • Revenue grew 43% year-over-year to $774 million in Q1 2026, exceeding prior expectations and validating the company’s growth trajectory.
  • Adjusted EBITDA reached $54 million, up 59% year-over-year, driven by revenue expansion and operating leverage across sales, marketing, and operations.
  • Net revenue retention (NRR) hit a record 127%, up from 115% in the prior year, reflecting strong existing brand partner growth and platform stickiness.
  • +7 more takeaways
NVO May 12, 2026

Novo Nordisk Q1 2026 Earnings Call - Wegovy Pill Uptake Offsets Price Erosion

Novo Nordisk’s Q1 2026 results reveal a company navigating a complex pricing environment while accelerating its commercial momentum. Adjusted sales fell 4% due to lower realized prices, but volume gro...

  • Adjusted sales declined 4% due to lower realized prices, partially offset by GLP-1 volume growth and market expansion.
  • Wegovy pill achieved record-breaking uptake, exceeding 1 million patients in just 16 weeks post-launch in the U.S.
  • The Wegovy franchise now holds approximately 65% new-to-brand (NBRX) market share in the U.S. anti-obesity medication space.
  • +7 more takeaways